BR112012019100A2 - composição de micela de polímero de ruptura. - Google Patents

composição de micela de polímero de ruptura.

Info

Publication number
BR112012019100A2
BR112012019100A2 BR112012019100A BR112012019100A BR112012019100A2 BR 112012019100 A2 BR112012019100 A2 BR 112012019100A2 BR 112012019100 A BR112012019100 A BR 112012019100A BR 112012019100 A BR112012019100 A BR 112012019100A BR 112012019100 A2 BR112012019100 A2 BR 112012019100A2
Authority
BR
Brazil
Prior art keywords
composition
polymer micelle
affinity
micelle composition
hdl
Prior art date
Application number
BR112012019100A
Other languages
English (en)
Inventor
Miho Ohuchi
Mitsunori Harada
Yasuki Kato
Original Assignee
Nanocarrier Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanocarrier Co Ltd filed Critical Nanocarrier Co Ltd
Publication of BR112012019100A2 publication Critical patent/BR112012019100A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

composição de micela de polímero de ruptura. a presente invenção provê uma composição de micela de polímero capaz de encapsular estavelmente e adequadmente liberar um fármaco e um composição farmacêutica usando a composição de micela de polímero. a composição de micela de polímero compreende copolímeros em bloco cada um tendo um segmento de cadeia de polímero hidrofóbico (12) e estrutura que uma pluralidade dos copolímeros em bloco é disposta radialmente em um estado em que o segmento de cadeia de polímero hidrofóbico (12) é dierecionado para fora. a composição inclui um copolímero em bloco10 tendo afinidade com hdl (20) como os copolímero em bloco. na composição, separação do copolímero em bloco (10) tendo afinidade com hdl (20) é induzida por adesão de hdl (20) atribuída à afinidade, então uma fenda formada através de separação causa promoção de liberação de um fármaco (50) a ser encapsulado. a composição permite controle de uma velocidade de liberação do fármaco a ser encapsulado através da inclusão adicional deu copolímero em bloco tendo afinidade com uma lipoproteína excluída hdl.
BR112012019100A 2010-02-05 2011-02-07 composição de micela de polímero de ruptura. BR112012019100A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010024323A JP4829351B2 (ja) 2010-02-05 2010-02-05 易崩壊型ポリマーミセル組成物
PCT/JP2011/052475 WO2011096558A1 (ja) 2010-02-05 2011-02-07 易崩壊型ポリマーミセル組成物

Publications (1)

Publication Number Publication Date
BR112012019100A2 true BR112012019100A2 (pt) 2016-09-13

Family

ID=44355551

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012019100A BR112012019100A2 (pt) 2010-02-05 2011-02-07 composição de micela de polímero de ruptura.

Country Status (13)

Country Link
US (1) US8574601B2 (pt)
EP (1) EP2433618B1 (pt)
JP (1) JP4829351B2 (pt)
KR (1) KR101777890B1 (pt)
CN (1) CN102781427B (pt)
AU (1) AU2011211631B2 (pt)
BR (1) BR112012019100A2 (pt)
CA (1) CA2788347A1 (pt)
ES (1) ES2528616T3 (pt)
HK (1) HK1166607A1 (pt)
RU (1) RU2555754C2 (pt)
TW (1) TWI538688B (pt)
WO (1) WO2011096558A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2554161A1 (en) * 2011-08-02 2013-02-06 LFB Biotechnologies Pharmaceutical composition comprising factor VII encapsulated in micelles
EP2842546A4 (en) 2012-04-27 2015-12-30 Univ Tokyo UNITARY STRUCTURE-TYPE PHARMACEUTICAL COMPOSITION FOR NUCLEIC ACID ADMINISTRATION
MX2015015334A (es) * 2013-05-17 2016-03-04 Nanocarrier Co Ltd Composicion farmaceutica de micela polimerica.
KR101507119B1 (ko) * 2013-05-31 2015-03-30 주식회사 바이오리더스 점막 점착성 폴리감마글루탐산 나노마이셀 및 이를 이용한 약물 전달체
KR102019973B1 (ko) 2013-11-20 2019-11-04 (주)바이오니아 마이크로 챔버 플레이트
JP6566936B2 (ja) 2014-05-08 2019-08-28 国立大学法人 東京大学 医薬組成物
WO2019009434A1 (ja) * 2017-07-06 2019-01-10 学校法人京都薬科大学 薬物送達用高分子ミセル
US11324835B2 (en) 2017-08-31 2022-05-10 Kawasaki Institute Of Industrial Promotion Nucleic acid-loaded unit polyion complex
EP3691779B1 (en) * 2017-10-06 2023-06-07 Université de Bordeaux Use of a copolymer for the stabilisation of an emulsion

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR940003548U (ko) 1992-08-14 1994-02-21 김형술 세탁물 건조기
JP2002179556A (ja) * 1992-10-26 2002-06-26 Nippon Kayaku Co Ltd ブロック共重合体−抗癌剤複合体医薬製剤
JPH0810341A (ja) * 1994-07-01 1996-01-16 Kankyo Hozen Kenkyusho:Kk 磁気治療器
ATE226966T1 (de) 1995-04-14 2002-11-15 Kazunori Kataoka Polyethylenoxide mit einer saccharidgruppe an einem ende und einer anderen funktionellen gruppe am anderem ende sowie verfahren zu deren herstellung
RU2169742C2 (ru) 1995-04-19 2001-06-27 Катаока Казунори Гетеротелехелатный блок-сополимер и способ его получения
NZ313769A (en) 1995-08-10 2000-02-28 Kazunori Kataoka block polymer having a functional group presented on each end
JPH10110019A (ja) 1996-10-08 1998-04-28 Kazunori Kataoka 安定化高分子ミセルおよび生理活性物質のキヤリヤーとしてのその使用
TW520297B (en) 1996-10-11 2003-02-11 Sequus Pharm Inc Fusogenic liposome composition and method
US6153596A (en) * 1996-12-18 2000-11-28 Emory University Polycationic oligomers
JPH11335267A (ja) * 1998-05-27 1999-12-07 Nano Career Kk 水難溶性薬物を含有するポリマーミセル系
FR2786098B1 (fr) 1998-11-20 2003-05-30 Flamel Tech Sa Particules a base de polyaminoacide(s) et susceptibles d'etre utilisees comme vecteurs de principe(s) actif(s), suspension colloidale les comprenant et leurs procedes de fabrication
ATE396707T1 (de) * 2000-12-01 2008-06-15 Biomira Inc Herstellung grosser liposome durch infusion in peg
FR2862536B1 (fr) * 2003-11-21 2007-11-23 Flamel Tech Sa Formulations pharmaceutiques pour la liberation prolongee de principe(s) actif(s), ainsi que leurs applications notamment therapeutiques
FR2862541B1 (fr) 2003-11-21 2007-04-20 Flamel Tech Sa Formulations pharmaceutiques pour la liberation prolongee d'interferons et leurs applications therapeutiques
FR2862535B1 (fr) * 2003-11-21 2007-11-23 Flamel Tech Sa Formulations pharmaceutiques pour la liberation prolongee d'interleukines et leurs applications therapeutiques
JP4344279B2 (ja) * 2004-05-28 2009-10-14 財団法人神奈川科学技術アカデミー 薬物送達用高分子ドラッグキャリヤーシステム
FR2902007B1 (fr) * 2006-06-09 2012-01-13 Flamel Tech Sa Formulations pharmaceutiques pour la liberation prolongee de principe(s) actif(s) ainsi que leurs applications notamment therapeutiques
EP2042184B1 (en) * 2006-07-18 2019-06-19 NanoCarrier Co., Ltd. Physiologically active polypeptide, polymer micelle having protein enclosed therein, and process for production of the polymer micelle
FR2904219B1 (fr) * 2006-07-28 2010-08-13 Flamel Tech Sa Microparticules a base de copolymere amphiphile et de principe(s) actif(s) a liberation modifiee et formulations pharmaceutiques en contenant
NZ575964A (en) 2006-10-19 2011-12-22 Nanocarrier Co Ltd Block copolymer for drug complex and pharmaceutical composition
EP2131814A4 (en) * 2007-02-26 2011-08-03 Wisconsin Alumni Res Found POLYMIC MICROMS FOR THE RELEASE OF ACTIVE COMPOUNDS
JP2008214324A (ja) 2007-02-28 2008-09-18 Hokkaido Univ ミセル封入リポソーム
EP2272897B1 (en) * 2008-03-10 2016-12-28 The University of Tokyo Copolymer including uncharged hydrophilic block and cationic polyamino acid block having lateral chain to which hydrophobic radical is partially introduced, and use of copolymer

Also Published As

Publication number Publication date
CN102781427A (zh) 2012-11-14
RU2012137711A (ru) 2014-03-10
KR101777890B1 (ko) 2017-09-12
AU2011211631B2 (en) 2016-05-12
JP2011162452A (ja) 2011-08-25
EP2433618A1 (en) 2012-03-28
CA2788347A1 (en) 2011-08-11
CN102781427B (zh) 2014-12-03
TW201143797A (en) 2011-12-16
US8574601B2 (en) 2013-11-05
JP4829351B2 (ja) 2011-12-07
RU2555754C2 (ru) 2015-07-10
ES2528616T3 (es) 2015-02-11
HK1166607A1 (en) 2012-11-02
EP2433618A4 (en) 2012-05-23
KR20120129901A (ko) 2012-11-28
TWI538688B (zh) 2016-06-21
AU2011211631A1 (en) 2012-07-12
EP2433618B1 (en) 2014-11-12
US20120093881A1 (en) 2012-04-19
WO2011096558A1 (ja) 2011-08-11

Similar Documents

Publication Publication Date Title
BR112012019100A2 (pt) composição de micela de polímero de ruptura.
BR112015026549A2 (pt) forma de dosagem à prova de violação contendo uma ou mais partículas
BR112014002022A2 (pt) comprimido resistente à violação proporcionando liberação de fármaco imediata
BR112017021475A2 (pt) forma de dosagem resistente à adulteração (tamper) com liberação imediata e resistência contra extração de solvente
BR112015005048A2 (pt) métodos para tratar dermatite atópica por administração de antagonista il-4r
BR112014014124A2 (pt) Moduladores do receptor de estrogênio fluorados e usos dos mesmos
BR112015022566A2 (pt) composto e composição farmacêutica
BR112018010018A2 (pt) moduladores de ror-gama
BR112013006395A2 (pt) moduladores do receptor de estrogênio e seus usos.
BR112018015273A2 (pt) derivados de benzimidazol como moduladores de ror-gama
BR112017008614A2 (pt) troca de contexto virtual acelerado de hardware
BR112015011403A2 (pt) uso de akkermansia para o tratamento de distúrbios metabólicos
BR112015002421A2 (pt) composição farmacêutica ou nutracêutica com características de liberação sustentada e com resistência contra a influência do etanol
BR112014001091A2 (pt) comprimido resistente à adulteração que fornece liberação imediata do fármaco
BR112014027155A2 (pt) composições de celúlas t deficientes do re-ceptor de células t
BR112015031903A2 (pt) composto, sal farmaceuticamente aceitável do composto, composição farmacêutica e utilização de um composto
BR112012020558A2 (pt) moduladores do receptor de androgênio e seus usos
BR112014016810A2 (pt) composições e métodos para tratamento de distúrbios metabólicos
BR112017003346A2 (pt) derivados de pirazolopiridina, seus usos, e composição farmacêutica
BR112014006661A2 (pt) acoplamento com anel de acoplamento em duas partes do acoplamento, e anel de acoplamento pertencente
BR112015030385A8 (pt) composto, composto para uso e composição farmacêutica
BR112013004440A2 (pt) método para administração parenteral de uma composição, composição farmacêutica para administração parenteral, kit e sistema farmacêutico para administração parenteral
BR112014017841A8 (pt) Processo para a preparação de uma composição condutora utilizando um masterbatch
BR112013017023A2 (pt) fibra e probióticos para a redução dos sintomas instestinais relacionados com o estresse
BR112017020307A2 (pt) método para inibir os sintomas associados com a ingestão de álcool, e, composição farmacêutica

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: NANOCARRIER CO., LTD. (JP)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2500 DE 04-12-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.